fda warning compounding semaglutide september 2025 Beyond the Headlines: Letters to GLP-1 Compounders US FDA warns online vendors

While the weight-reducing effects of GLP-1 agonists are well documented in metabolic disorders, there are limited data regarding their use in managing endocrine therapy-associated weight gain

Addressing Lillys Competitive Advantages Doustdar confronted potential advantages for Lillys orforglipron, which lacks the fasting requirements associated with oral Wegovy

These include type 2 diabetes, allergies and colorectal cancer

The mechanism that lowers postprandial glucose also means the stomach retains contents longer, which is relevant to anyone with pre-existing gastroparesis or significant GI motility disorders, and is a theoretical consideration around procedures requiring an empty stomach